¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"low malignant potential tumor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • electric potential
    Àü±âÀüÀ§, ÀüÀ§
  • electric potential gradient
    ÀüÀ§±â¿ï±â
  • electrochemical potential
    Àü±âÈ­ÇÐÀüÀ§
  • electrochemical potential gradient
    Àü±âÈ­ÇÐÀüÀ§±â¿ï±â
  • electrode potential
    Àü±ØÀüÀ§
  • electrotonic potential
    Àü±â±äÀåÀüÀ§
  • endocochlear potential
    ´ÞÆØÀ̳»ÀüÀ§, ¿Í¿ì³»ÀüÀ§
  • endplate potential
    Á¾¸»ÆÇÀüÀ§, Á¾ÆÇÀüÀ§
  • fasciculation potential
    ±Ù(À°)¼¶À¯´Ù¹ß¼öÃàÀüÀ§
  • fibrillation potential
    ¼¶À¯ÀÚ¹ßÀüÀ§
  • generator potential
    ¹ß»ý±âÀüÀ§, ±âµ¿ÀüÀ§
  • giant potential
    °Å´ëÀüÀ§
  • inhibitory postsynaptic potential
    ¾ïÁ¦½Ã³ÀÀÌÈÄÀüÀ§, ¾ïÁ¦¿¬Á¢ÀÌÈÄÀüÀ§
  • injury potential
    ¼Õ»óÀüÀ§
  • junctional potential
    Á¢ÇÕºÎÀüÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • critical membrane potential
    ÀӰ踷ÀüÀ§
  • cutaneous nerve somatosensory evoked potential
    Ç¥ÇǽŰæ¸ö°¨°¢À¯¹ßÀüÀ§
  • demarcation potential
    ºÐ°èÀüÀ§
  • denervation potential
    Å»½Å°æÀüÀ§
  • diffusion potential
    È®»êÀüÀ§
  • disease potential
    Áúº´ÀáÀç·Â
  • potential difference
    Àü¾ÐÂ÷, ÀüÀ§Â÷
  • total potential energy difference
    ÃÑÀ§Ä¡¿¡³ÊÁöÂ÷
  • transmembrane potential difference
    ¸·ÀüÀ§Â÷ÀÌ
  • early receptor potential
    Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • electric potential
    ˟ˤ
  • electric potential gradient
    ÀüÀ§±â¿ï±â
  • electrochemical potential
    Àü±âÈ­ÇÐÀüÀ§
  • electrochemical potential gradient
    Àü±âÈ­ÇÐÀüÀ§±â¿ï±â
  • electrode potential
    Àü±ØÀüÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
  • malignant anemia
    ¾Ç¼ººóÇ÷(ç÷àõÞ¸úì).
  • malignant anemia
    ¾Ç¼ººóÇ÷(ËçËÛË×Ì´).
  • malignant angioendotheliomatosis
    ¾Ç¼º Ç÷°ü ³»ÇÇÁ¾Áõ
  • malignant anthrax
    ¾Ç¼ºÅºÀú(ç÷àõ÷©îÅ).
  • malignant aphthae
    ¾Ç¼º¾ÆÇÁŸ.
  • malignant atrophic papulosis = Degos disease
    ¾Ç¼º À§Ã༺ ±¸ÁøÁõ
  • malignant baloon cell nevus
    ¾Ç¼º dz¼±¼¼Æ÷ ¸ð¹Ý
  • malignant blue nevus
    ¾Ç¼º û»ö ¸ð¹Ý
  • malignant cachexia
    ¾Ç¼º¾Ç¾×Áú(¡­ç÷äûòõ).
  • malignant carcinoid
    ¹æ»ç ¾Ç¼ºÄ«¸£½Ã³ëÀ̵å, ¾Ç¼º À¯¾ÏÁ¾.
  • malignant carcinoid syndrome
    ¾Ç¼ºÄ«¸£½Ã³ëÀ̵åÁõÈıº.
  • malignant cell
    ¾Ç¼º¼¼Æ÷(ç÷àõá¬øà).
  • malignant change
    ¾Ç¼ºº¯È­(¡­Ü¨ûù).
  • malignant cholera
    ¾Ç¼ºÄÝ·¹¶ó.
  • malignant chondroid syringoma
    ¾Ç¼º ¿¬°ñ¼º ÇѰüÁ¾
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
MTV mammary tumor virus; metatarsus varus; mouse mammary tumor virus
NET nasoendotracheal tube; nerve excitability test; neuroectodermal tumor; neuroendocrine tumor; norepin...
TC target cell; taurocholate; temperature compensation; teratocarcinoma; tertiary cleavage; tetracyclin...
TIF tumor-inducing factor; tumor-inhibiting factor
TIL tumor-infiltrating leukocyte; tumor-infiltrating lymphocyte
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 9
APD90 action potential durations at 90% repolarization
ATP Annual Transmission Potential
APT Applied Potential Tomography
BP Binding potential
BSPM body surface potential map
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • endometrioid tumor
    Àڱà ³»¸·¾ç Á¾¾ç
  • exophytic mucosal tumor
    ¿ÜÇ⼺ Á¡¸· Á¾¾ç
  • exophytic tumor
    ¿ÜÇ⼺ Á¾¾ç
  • fibroid tumor
    ¼¶À¯¾ç Á¾¾ç
  • fibroma-theca cell tumor
    ¼¶À¯Á¾-³­Æ÷¸· ¼¼Æ÷Á¾
    ¼¶À¯¾Æ¼¼Æ÷³ª ³­Æ÷¸· ¼¼Æ÷·Î ±¸¼ºµÈ´Ù. ±¸¼º ¼¼Æ÷°¡ ´ëºÎºÐ ³­Æ÷¸· ¼¼Æ÷ÀÎ ÀÌ Á¾¾çÀº È£¸£¸óÀ» »ý»êÇÒ ¼ö ÀÕ´Ù. ±×·¯³ª ¼ø¼öÇÑ ³­Æ÷¸· ¼¼Æ÷Á¾Àº µå¹°°í ´ëºÎºÐ Á¾¾çÀº ÁÖ·Î ¼¶À¯¸ð¼¼Æ÷·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç È£¸£¸óÀ» »ý»êÇÏÁö ¾Ê´Â´Ù. 90%¿¡¼­ ÇÑÂÊ ³­¼Ò¿¡¼­¸¸ ¹ß»ýÇÑ´Ù. Á¾¾çÀº ȸ¹é»öÀÌ¸ç °íÇüÀÌ°í ±¸ÇüÀÌ¸ç ´Ü´ÜÇÏ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î ¼¶À¯¸ð¼¼Æ÷¿Í ÄݶóÁ¨ °áü Á¶Á÷À¸·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç ³­Æ÷¸· ¼¼Æ÷°¡ È¥ÀçÇÒ ¼ö ÀÖ´Ù. ȯÀÚ´Â °ñ¹ÝÅë°ú °ñ¹Ý Á¾±« µîÀÇ ºñƯÀÌÀû Áõ»óÀ» È£¼ÒÇϰųª º¹¼ö°¡ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ³­Æ÷¸· ¼¼Æ÷Á¾Àº ¾Ç¼ºÀÌ ¾ø´Ù.
  • hormone dependent tumor
    È£¸£¸ó ÀÇÁ¸¼º Á¾¾ç
  • induced tumor
    Àΰø ¾Ï
    µ¿¹°¿¡°Ô ÀΰøÀûÀÎ ¾Ï¿ø¼º ÀÚ±ØÀ» ÁÖ¾î Çü¼º½ÃŲ ¾Ï. µ¿¹°ÀÇ ÀÚ¿¬¹ß»ý ¾Ï¿¡ ´ëÀÀÇÏ´Â ¸»ÀÌ´Ù.
  • intraosseous salivary gland tumor
    °ñ³» Ÿ¾×¼± Á¾¾ç
  • juxtaglomerular cell tumor
    ¹æ»ç±¸Ã¼ ¼¼Æ÷ Á¾¾ç
  • juxtaglomerular tumor
    ¹æ»ç±¸Ã¼ Á¾¾ç
  • krukenberg's tumor
    Å©·çÄ˺£¸£Å© Á¾¾ç
  • lacteal tumor
    À¯¼± Á¾¾ç
  • large tumor
    Å« Á¾¾ç
  • lingual benign giant cell tumor
    ¾ç¼º °Å´ë ¼¼Æ÷ ¼³ Á¾¾ç
  • lingual tumor
    ¼³ Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 9
malignant granuloma Destruction of the nasal septum, hard palate, lateral nasal walls, paranasal sinuses, skin of the face, orbit and nasopharynx by an inflammatory infiltrate with atypical lymphocytic and histiocytic cells; presumably a form of lymphoma in most cases.
An obsolete term for polymorphic reticulosis.
Synonym: granuloma gangrenescens, malignant granuloma, midline malignant reticulosis granuloma.
(05 Mar 2000)
malignant hepatoma <tumour> A carcinoma derived from parenchymal cells of the liver.
Synonym: hepatocarcinoma, hepatocellular carcinoma, liver cell carcinoma.
(05 Mar 2000)
malignant histiocytosis A rapidly fatal form of lymphoma, characterised by fever, jaundice, pancytopenia, and enlargement of the liver, spleen, and lymph nodes; the affected organs show focal necrosis and haemorrhage, with proliferation of histiocytes and phagocytosis of red blood cells.
(05 Mar 2000)
malignant hyperphenylalaninaemia DHPR-deficient form; an inherited disorder in which there is an absence or deficiency of dihydropteridine reductase (DHPR); this results in impaired regeneration of tetrahydrobiopterin, causing an elevation in phenylalanine levels, GTP-CH form; an inherited disorder in which there is a deficiency of guanosine triphosphate cyclohydrolase, an enzyme used in the biosynthesis of tetrahydrobiopterin, 6-PTS form; an inherited disorder in which there is a deficiency of 6-pyruvoyl tetrahydropterin synthase, an enzyme that participates in the biosynthesis of tetrahydrobiopterin.
Synonym: nonclassical phenylketonuria.
(05 Mar 2000)
malignant hyperpyrexia A severe and often fatal illness produced by exposure to excessively high temperatures, especially when accompanied by marked exertion.
It can manifest by elevated body temperature, lack of sweating, hot dry skin, and neurologic symptoms; unconsciousness, paralysis, headache, vertigo, confusion. In severe cases very high fever, vascular collapse, and coma develop.
Synonym: heat apoplexy, heat hyperpyrexia, malignant hyperpyrexia, thermic fever.
(05 Mar 2000)
malignant hypertension A severe form of acute hypertension that results in the abrupt rise in the blood pressure (diastolic pressure often over 120 mmHg). If left untreated, malignant hypertension can cause damage to the blood vessels in the eye, kidneys, brain and heart. Complications include stroke, heart attack, blindness and renal failure.
Symptoms include headache, blurred vision, nausea, vomiting and lethargy. Neurologic symptoms are also a common finding. Malignant hypertension occurs more commonly in males, African Americans and those with a history for hypertension.
(27 Sep 1997)
malignant hyperthermia A severe form of fever that occurs as a reaction to certain anaesthetic agents and muscle relaxants. Malignant hyperthermia is an inherited autosomal dominant condition.
Inheritance: autosomal dominant.
(27 Sep 1997)
malignant jaundice Jaundice associated with high fever and delirium; seen in severe hepatitis and other diseases of the liver with severe functional failure.
Synonym: malignant jaundice.
(05 Mar 2000)
malignant lentigo melanoma <tumour> A melanoma arising from a malignant lentigo.
(05 Mar 2000)
malignant liver tumours <radiology> EPITHELIAL TUMORS, hepatocellular, hepatoblastoma (7%), hepatocellular carcinoma (HCC) (75%), cholangiocellular (6%), cholangiocarcinomarcinoma, cystadenocarcinoma, MESENCHYMAL TUMORS, tumours of blood vessels, angiosarcoma, haemangioendothelioma, other tumours, embryonal sarcoma, fibrosarcoma, TUMORS OF MUSCLE TISSUE, leiomyosarcoma, rhabdomyosarcoma, MISCELLANEOUS, carcinosarcoma, teratoma, yolk sac tumour, carcinoid, squamous carcinoma, primary lymphoma see: benign liver tumours
(12 Dec 1998)
malignant lymphadenosis An obsolete term for malignant lymphoma.
(05 Mar 2000)
malignant lymphoma <tumour> A general term for ordinarily malignant neoplasms of lymphoid and reticuloendothelial tissues which present as apparently circumscribed solid tumours composed of cells that appear primitive or resemble lymphocytes, plasma cells, or histiocytes. Lymphomas appear most frequently in lymph nodes, spleen, or other normal sites of lymphoreticular cells; when disseminated, Lymphoma's, especially of the lymphocytic type, may invade the peripheral blood and manifest as leukaemia. Lymphomas are classified by cell type, degrees of differentiation, and nodular or diffuse pattern; Hodgkin's disease and Burkitt's lymphoma are special forms.
(05 Mar 2000)
malignant malnutrition A nutritional deficiency illness in children who are not getting enough protein, this results in anaemia, poor growth, weakness, and oedema (which isparticularly characterised by a pronounced pot belly). Infamine-stricken regions, children typically develop kwashiorkor rightafter they are weaned.
(09 Oct 1997)
malignant melanoma <oncology, tumour> A malignant tumour which arises from the pigment producing cells (melanosomes) of the deeper layers of the skin (or the eye). Melanoma is the leading cause of death attributable to skin lesions. Described as an irregular dark skin lesion that may have areas of varying colour. Often greater than 6 mm in diameter.
(27 Sep 1997)
malignant melanoma: gallium imaging <radiology> Greater than50% sensitivity for primary and metastatic sites: 73% sensitivity if lesion is greater than 2 cm, 17% sensitivity if less than 2 cm, see: gallium: indications malignant melanoma
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 9
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 9
ÅëÇÕ°Ë»ö ¿Ï·á